Technology | Contrast Media | February 02, 2017

Lantheus Medical Imaging Announces FDA Approval of Definity Label Update

Label revision removes cardiac shunt contraindication

Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication

February 2, 2017 — Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension. The update removes the contraindication statement related to use in patients with a known or suspected cardiac shunt from the U.S. Prescribing Information.

Definity is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal path of the circulatory system, which may present in 10 to 35 percent of patients. These patients were previously excluded from receiving a valuable echo contrast study of the left ventricle. The FDA’s decision to remove the contraindication concerning known or suspected cardiac shunts was based on Lantheus’ submission referencing several publications and data supporting the safety of echocardiography contrast products in patients with cardiac shunts. Information concerning administration in patients with a cardiac shunt appears in the Warnings section of the Definity Prescribing Information.

Neil Weissman, M.D., president of MedStar Health Research Institute (Washington, D.C.), professor of medicine at Georgetown University and past president of the American Society of Echocardiography commented, “The echocardiography medical and scientific community has long demonstrated the safety of echocardiographic contrast agents through published clinical studies which has supported the removal of the contraindication for Definity in patients with cardiac shunts. This is particularly noteworthy as Definity is the most widely used echocardiography agent in the U.S. with published data supporting its safety profile across multiple care settings and across gender and race in adults, including those age 65 and older.”

Weissman continued, “This is an important step toward broader acceptance and appropriate use of echo contrast agents, which can safely and cost effectively provide critical information to help clinicians accurately diagnose and manage patients to achieve better outcomes.”

Up to 20 percent of all resting echocardiography studies and up to 30 percent of those conducted in critical care patients can result in suboptimal echocardiograms. A suboptimal image is one in which two or more contiguous left ventricular segments in any of the three apical views cannot be visualized. The use of contrast in suboptimal echocardiograms may help with clinical evaluation of the patient.

For more information: www.lantheus.com

Related Content

Bay Labs and Northwestern Medicine Enroll First Patient in AI Echocardiography Study
News | Cardiovascular Ultrasound | November 19, 2018
Medical artificial intelligence (AI) company Bay Labs and Northwestern Medicine announced that the first patient has...
QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018
News | Ultrasound Women's Health | November 19, 2018
QView Medical will showcase QVCAD, the first U.S. Food and Drug Administration (FDA)-approved artificial intelligence (...
SuperSonic Imagine Introduces Aixplorer Mach 30 Ultrasound at The Liver Meeting
Technology | Ultrasound Imaging | November 14, 2018
SuperSonic Imagine recently exhibited at The Liver Meeting, held Nov. 9-13 in San Francisco, where the company...
Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply
News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...
New Robotic Arm System Optimizes Testing of Ultrasound Probes

Image courtesy of Esaote

News | Ultrasound Imaging | November 09, 2018
Medical imaging company Esaote and The BioRobotics Institute of Scuola Superiore Sant’Anna in Pisa, Italy, have...
The Acuson Sequoia

The Acuson Sequoia from Siemens Healthineers.

Feature | Ultrasound Imaging | November 05, 2018 | By Jeff Zagoudis
As the world’s most utilized medical imaging modality, ultrasound is likely to be featured heavily at the 2018...
Fujifilm SonoSite Launches New Point-of-Care Ultrasound Educational Resources
News | Ultrasound Imaging | November 01, 2018
Fujifilm SonoSite Inc. announced the launch of its redesigned SonoSite Institute, a comprehensive online educational...
Vygon and Sonoscanner Partnering on New Ultrasound System for Catheter Placement Guidance
News | Cardiovascular Ultrasound | October 31, 2018
Vygon, an international group specialized in single-use medical devices, and French company Sonoscanner announced the...
Cardiac Ultrasound Software Streamlines Fetal Heart Exams
Feature | Cardiovascular Ultrasound | October 30, 2018
A new tool called fetalHQ on GE Healthcare’s Voluson ultrasound systems is the first tool to simultaneously examine the...
Hitachi Supports ASE Foundation Cardiovascular Outreach Mission in West Virginia
News | Cardiovascular Ultrasound | October 29, 2018
Hitachi Healthcare Americas participated in the cardiovascular screening and diagnostic triage event that took place...